A selective, sector-specific program for four Korean FemTech and women's health companies — combining roughly two weeks of company and institutional preparation with three days of matched New Jersey institutional access, and initial follow-through afterward.
Check FemTech Eligibility How the Sprint Works →The FemTech Sprint is a limited 2026 pathway — it is not a replacement for the 90-Day U.S. Market Activation Program.
The introduction is not the product. The preparation and execution around it are.
Most companies do not fail in New Jersey because they lacked a meeting. They fail because they arrived unprepared for the questions U.S. institutions ask first. The Sprint spends two weeks making each company understandable and credible before it ever walks into a room — then structures three days of engagement around a defined business objective.
The fee is not admission to an event. The majority of the work happens before anyone arrives in New Jersey — and the follow-through continues after everyone leaves.
The Sprint fee is not comparable to a conference registration. It buys individualized professional work across strategy, institutional relations, communications and coordination.
Allocated according to your company's readiness, institutional pathway and program needs — spanning positioning, pitch preparation, institutional targeting and meeting briefs.
The three-day New Jersey program and its on-site coordination are provided in addition to your individualized hours — not drawn from them.
The cohort is limited to four because each company requires individual preparation, institutional targeting and program coordination before arriving in New Jersey. Four is the number KCED can prepare to this standard — not a marketing constraint.
The $899 Diagnostic is a professional deliverable, not an application fee. Companies that are not selected keep their Diagnostic & Roadmap and owe no remaining FemTech balance.
For selected FemTech companies, the $899 Diagnostic already paid is credited toward the program:
The $7,900 FemTech Sprint contains its own compressed, sector-specific preparation. Selected cohort companies do not stack the separate 30-Day U.S. Market Readiness Sprint on top of it.
Extra creative work requires additional written scope.
KCED works with companies where there is a credible U.S. market-entry case and a defined institutional pathway. The Sprint is best suited to companies prepared to provide substantive materials, engage senior leadership, and act on the resulting roadmap.
Selected companies are identified publicly only after their written permission.
The professional program above stands on its own. Hospitality, logistics and dedicated interpretation are optional and secondary to the institutional value.
Optional coordination of local hospitality and logistics during the New Jersey program.
Basic bilingual program coordination may be included; dedicated professional interpretation is priced separately.
In October 2025, KCED organized and hosted Bio Summit 2025 at Liberty Science Center — preparing Korean companies, convening institutional participants, coordinating the program, and managing follow-through. The 2026 FemTech Track applies that operating model to a smaller, more selective and more deeply prepared cohort.
Company preparation, institutional participation, program coordination and documented follow-through at Liberty Science Center. Report →
A smaller, sector-specific and more deeply prepared cohort of four, focused on FemTech and women's health.
No. KCED prepares and coordinates matched institutional engagement based on relevance, interest and availability. The value is in the preparation and coordination, not a promise of specific meetings.
Because the program includes approximately two weeks of company and institutional preparation before the three-day New Jersey program — not just the event days themselves.
No. It is a standalone professional Diagnostic & Roadmap. For selected companies it is credited toward the program ($7,900 − $899 = $7,001). Companies not selected keep their Diagnostic and owe no remaining FemTech balance.
No. The $7,900 FemTech Sprint contains its own compressed, sector-specific preparation. Selected cohort companies do not stack the $6,500 Sprint on top of it.
Yes — roughly two weeks of company-side and institutional-side preparation before arrival is the core of the fee, including up to ~20 hours of individualized professional services.
Initial follow-through (~14 days) is included. Longer-term execution is not; if meaningful opportunities require continued work, companies transition to the 90-Day U.S. Market Activation Program.
Content review, institutional positioning and defined pitch preparation are included. Full graphic redesign is not, unless separately contracted.
No. Optional hospitality and local-logistics support is available and priced separately, from $2,600 per executive.
Basic bilingual program coordination may be included. Dedicated professional interpretation is $600 per day.
Initial follow-through is included. Longer-term execution may continue through the 90-Day U.S. Market Activation Program.
No. Applications are reviewed and the cohort of four is selected on fit. The Sprint is not a replacement for the 90-Day Activation Program; it is a limited 2026 pathway.
No. KCED identifies issues and coordinates with qualified outside professionals where necessary. KCED does not provide legal, regulatory, medical, tax or investment advice.
Four companies. Applications close September 15, 2026. Tell us where your company stands and what you want to achieve in the U.S. market.
Check FemTech Eligibility